Clinical Trial Update: The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial [Phase 3]

View source ↗

Summary

The Phase 3 CANTATA-M trial evaluating canagliflozin as monotherapy in adults with Type 2 diabetes has completed, and results were posted in June 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2013-06-03